Quantum Biopharma Q3 2023 Earnings Report $3.76 -0.13 (-3.34%) As of 01/8/2025 04:00 PM Eastern Earnings History Quantum Biopharma EPS ResultsActual EPS-$1.95Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AQuantum Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQuantum Biopharma Announcement DetailsQuarterQ3 2023Date11/14/2023TimeN/AConference Call ResourcesQNTM Earnings History URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Quantum Biopharma Earnings HeadlinesQuantum BioPharma approved to dual list on UpstreamJanuary 8 at 4:44 PM | markets.businessinsider.comQuantum Biopharma Ltd.: Quantum Biopharma Announces Closing of Second TrancheDecember 20, 2024 | finanznachrichten.deDo this to position yourself after last month’s tech’s tumble… A lot of investors saw a significant portion of their portfolio erased after $1.7 trillion was wiped out of the Magnificent 7… Now they’re scratching their heads trying to figure out where to invest their money going forward. Well, you won’t need to search for long because the pullback from mega-cap tech is allowing other sectors and smaller companies to stand out… Setting up what could be a massive once-in-a-lifetime “double dip” opportunity on an often overlooked class of stocks. I’m talking about small cap stocks that pay dividends every month… January 9, 2025 | DTI (Ad)Quantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in CryptocurrencyDecember 20, 2024 | globenewswire.comHow This $4 Stock is Taking on Wall Street's Big Banks with a $700 Million LawsuitDecember 18, 2024 | msn.comQuantum BioPharma Advances Lucid-21-302 Clinical TrialDecember 11, 2024 | markets.businessinsider.comSee More Quantum Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email. Email Address About Quantum BiopharmaQuantum Biopharma (NASDAQ:QNTM), a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.View Quantum Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
